Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1 26Phase 1/2 22Phase 3 14Phase EARLY_PHASE1 2Phase 2/3 2Phase 4 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 5Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Waldenstrom Macroglobulinemia 1Prostatic Neoplasms 1Neurotoxicity Syndromes 1Neuroblastoma 1Neoplasms 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Graft vs Host Disease 1Central Nervous System Neoplasms 1

Interventions

Rituximab 2venetoclax 1tafasitamab 1pembrolizumab 1glofitamab 1fludarabine 1avelumab 1Valproic Acid 1Melphalan 1Ifosfamide 1Gemcitabine 1Etoposide 1Dexamethasone 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lymphoma, B-Cell × Rituximab × Clear all
NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

NCT00515138 2012-04-12

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

University of California, San Francisco

Phase EARLY_PHASE1 Terminated
7 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡